Method for diagnosing collagen degradatation associated disease

The Inventors have developed an ELISA of a new molecular marker detecting a neoepitope generated from the cleavage of the α1 chain of type III collagen within its helical domain. Serum levels of this marker were significantly increased in patients with RA and is significantly associated to CRP and ESR levels. Indeed, they demonstrated that the median serum HELIX-III levels were significantly higher in patients with moderate (p=0027) and active RA (p=00004) compared with those in age-matched controls.
The present invention relates to an antibody recognizing an epitope having SEQ ID NO :1 of collagen protein and its uses for diagnostic, prognostic and monitoring purposes.

Keywords: Rheumatoid Arthritis, collagene degradation, prognosis
Patent Application number: European Procedure (Patents) (EPA) - 01 Févr. 2022 - 22 305 111.1
Inventors:
CHAPURLAT Roland,GARNERO Patrick,GINEYTS Evelyne

Reference:

BIO21443-D1

Business Developper
contact
Inserm Transfert
Business Developer
Patent filling date: 01-02-2022
Rare disease: No
Second indication: No

You might also be interested in